Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions

Journal of Clinical Investigation

Volumn 104, Issue 11, 1999, Pages 1507-1515

  Dubois, Bénédicte ^a   Masure, Stefan ^a   Hurtenbach, Ursula ^b   Paemen, Liesbet ^a   Heremans, Hubertine ^a   Van Den Oord, Joost ^c   Sciot, Raf ^c   Meinhardt, Thorsten ^b   Hämmerling, Günter ^b   Opdenakker, Ghislain ^a   Arnold, Bernd ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CATALYSIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; ONTOGENY; PRIORITY JOURNAL;

EID: 0033405694     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6886     Document Type: Article

References (58)

1. Agren, M.S., Jorgensen, L.N., Andersen, M., Viljanto, J., and Gorrrup, F. 1998. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br. J. Surg, 85:68-71.
2. Tsafriri, A. 1995. Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Adv. Exp. Med. Biol. 377:121-140.
3. Sharkey, M.E., Adler, R.R., Nieder, G.L., and Brenner, C.A. 1996 Matrix metalloproteinase expression during mouse peri-implantation development. Am. J. Reprod. Immnnol. 36:72-80.
4. Vu, T.H., et al. 1998. MMP-9/Gelatinase B is a key regulator of growth place angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
5. Vu, T.H., and Werb, Z. 1998. Gelatinase B: struccure, regulation, and function. In Matrix metalloproteinases. W.C. Parks and R.P. Mecham, editors. Academic Press. San Diego, CA. 115-137.
6. Hua, J., and Muschel, R.J. 1996. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56:5279-5284.
7. van den Oord, J.J., Paemen, L., Opdenakker, G., and de Wolf-Peeters, C. 1997. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am. J. Pathol. 151:665-670.
8. Opdenakker, G., Masure, S., Grillet, B., and Van Damme, J. 1991. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 10:317-324.
9. Makela, M., Salo, T., Ditto, V.J., and Larjava, H. 1994. Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J. Dent. Res. 73:1397-1406.
10. Gijbels, K., Masure, S., Carton, H., and Opdenakker, G. 1992. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:29-34.
11. Paemen, L., Olsson, T., Söderström, M., Van Damme, J., and Opdenakker, G. 1994. Evaluation of gelatinases and IL-6 in the cerebrospmal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1:55-63.
12. Maeda, A., and Sobel, R.A. 1996. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp Neurol. 55:300-309.
13. Cuzner, M.L., et al. 1996. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1194-1204.
14. Cossins, J.A., et al. 1997. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 94:590-598.
15. Galis, Z.S., Sukhova, G.K., Lark, M.W., and Libby, P. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503.
16. Backstrom, J.R., Lim, G.P., Cullen, M.J., and Tökés, Z.A. 1996. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40). J. Neurosci. 16:7910-7919.
17. Paemen, L., et al. 1997. Induction of gelatinase B and MCP-2 in baboons during sublethal and lethal bacteraemia. Cytokine. 9:412-415.
18. Murphy, G., and Docherty, A.J.P. 1992. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell Mol. Biol. 7:120-125.
19. Opdenakker, G., and Van Damme, J. 1994. Cytokine-regulated proteases in autoimmune diseases. Immunol. Today. 15:103-107.
20. Werb, Z. 1997. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:439-442.
21. Van Wart, H.E., and Birkedal-Hansen, H. 1990. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87:5578-5582.
22. Cuzner, M.L., and Opdenakker, U. 1999. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94:1-14.
23. Masure, S., Proost, P., Van Damme, J., and Opdenakker, G. 1991. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukm-8. Eur. J. Biochem. 198:391-398.
24. Wuyts, A., et al. 1996. Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammarory protein-2. J. Immunol. 157:1736-1743.
25. Johnatty, R.N., et al. 1997. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol. 158:2327-2333
26. Pagenstecher, A., Stalder, A.K., Kincaid, C.L., Shapiro, S. D., and Campbell, I.L. 1998. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152:729-741.
27. Mazzieri, R., et al. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 16:2319-2332.
28. Lijnen, H.R., Silence, J., Van Hoef, B., and Collen, D. 1998. Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood. 91:2045-2053.
29. Yong, V.W., Krekoski, C.A., Forsyth, P.A., Bell, R., and Edwards, D.R. 1998. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21:75-80.
30. Proost, P., Van Damme, J., and Opdenakker, G. 1993. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192:1175-1181.
31. Gijbels, K., et al. 1993. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36:432-440
32. Chandler, S., et al. 1995. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201:223-226.
33. Leppert, D., Waubant, E., Galardy, R., Bunnett, N.W., and Hauser, S.L. 1995. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:4379-4389.
34. Rosenberg, G.A., Dencoff, J.E., Correa, N., Reiners, M., and Ford, C.C. 1996. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrter injury. Neurology, 46:1626-1632.
35. Schönbeck, U., Mach, F., and Libby, P. 1998. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161:3340-3346.
36. Paemen, L., Martens, E., Masure, S., and Opdenakker, G. 1995. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem. 234:759-765.
37. Wekerle, H., Kojima, K., Lannes-Vieira, J., Lassman, H., and Linington, C. 1994. Animal models. Ann. Neurol. 36:S47-S53.
38. Swanborg, R.M. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77:4-13.
39. Kieseier, B.C., et al. 1998. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 121:159-166.
40. Brosnan, C.F., Cammer, W., Norton, W.T., and Bloom, B.R. 1980. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature. 285:235-237.
41. Inuzuka, T., Sato, S., Baba, H., and Miyatake, T. 1988. Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE). Neurochem. Res. 13:225-228.
42. Gijbels, K., Galardy, R.E., and Steinman. L. 1994. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloprotease. J. Clin. Invest. 94:2177-2182.
43. Hewson, A.K., Smith, T., Leonard, J.P. and Cuzner, M.L. 1995. Suppression of experimental allergic encephalomyelitis in the Lewis rar by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:345-349.
44. Norga, K., et al. 1995. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm. Res. 44:529-534.
45. Clements, J.M., et al. 1997. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J. Neuroimmunol. 74:85-94.
46. Leppert, D., Waubant, H., Bürk, M.R., Oksenberg, J.R., and Hauser, S.L. 1996. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:846-852.
47. Stüve, O., et al. 1996. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:853-863.
48. Masure, S., Nys, G., Fiten, P., Van Damme, J., and Opdenakker, G. 1993. Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur. J. Biochem. 218:129-141.
49. Baker, D., O'Neill, J.K., Davison, A.N., and Turk, J.L. 1992. Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin. Exp. Immunol. 90:124-128.
50. Liu, Z., et al. 1998. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 188:475-482.
51. Rudolph-Owen, L.A., Hulboy, D.L., Wilson, C.L., Mudgett, J., and Matrisian, L.M. 1997. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology. 138:4902-4911.
52. Shipley, J.M., Wessclschmidt, R.L. Kobayashi, D.K., Ley, T.J., and Shapiro, S.D. 1996. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. USA. 93:3942-3946.
53. Itoh, T., et al. 1997. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. 272:22389-22392.
54. Itoh, T., et al. 1998. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1048-1051.
55. Wilson, C.L., Heppner, K.J., Labosky, P.A., Hogan, B.L.M., and Matrisian, L. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA. 94:1402-1407.
56. Mudgett, J.S., et al. 1998. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41:110-121.
57. Shapiro, S.D. 1997. Mighty mice: transgenic technology "knock out" questions of matrix metalloproteinase function. Matrix Biol. 15:527-533.
58. Steinman L. 1997. Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med. 185:2039-2041.